Cost of Revenue: Key Insights for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated

Cost of Revenue: Takeda vs. Corcept, 2014-2023

__timestampCorcept Therapeutics IncorporatedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014882000520990000000
Thursday, January 1, 20151361000535405000000
Friday, January 1, 20162058000558755000000
Sunday, January 1, 20173554000495921000000
Monday, January 1, 20185215000659690000000
Tuesday, January 1, 201955040001089764000000
Wednesday, January 1, 20205582000994308000000
Friday, January 1, 202152810001106846000000
Saturday, January 1, 202253850001244072000000
Sunday, January 1, 202364810001431505000000
Monday, January 1, 20241431505000000
Loading chart...

Data in motion

Analyzing Cost of Revenue Trends: Takeda vs. Corcept

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated from 2014 to 2023. Takeda, a global leader, has seen its cost of revenue grow by approximately 175% over the decade, peaking at 1.43 trillion in 2023. This reflects its expansive operations and market reach. In contrast, Corcept, a niche player, experienced a 635% increase, reaching 6.48 million in 2023, highlighting its strategic growth in specialized therapies.

The data reveals Takeda's consistent upward trajectory, with a notable surge post-2018, likely due to strategic acquisitions and product launches. Meanwhile, Corcept's growth, though smaller in absolute terms, underscores its focused approach in the biotech sector. Missing data for 2024 suggests ongoing developments, making future trends worth watching.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025